Alto Neuroscience Q3 2026 Results: Net Loss of $25.1M, Loss Widens
Alto Neuroscience reported a net loss of $79.0 million for the nine months ended September 30, 2026, compared to $47.1 million in the prior year, driven by a significant increase in research and development expenses. The company strengthened its balance sheet through a private placement and direct shelf offering, ending the period with $319.3 million in cash and cash equivalents.
- Key figure
- Net loss $25.1M